Watson Settles Androderm False Marking Suit
Watson Pharmaceuticals Inc. has agreed to stop using packaging for its Androderm testosterone deficiency treatment allegedly labeled with expired patents in order to settle a false marking suit accusing the company...To view the full article, register now.
Already a subscriber? Click here to view full article